This study was aimed to investigate the therapeutic potential of novel nonclassical antifolate, 2-[N-(2´-Hydroxyethyl)amino]methyl-3H-quinazolin-4-one (HEAMQ), toward human promonocytic U937 and murine lymphoblastic L1210 cell lines. The antiproliferative activity of HEAMQ was determined by MTT assay and its effects on cell cycle progression and apoptosis were studied by flow cytometry, and by immunoblots, respectively. In addition, combination chemotherapy of HEAMQ with cisplatin and temozolomide under in vitro and in vivo conditions was tested. HEAMQ showed concentration-and time-dependent cytotoxicity toward U937 and L1210 cells. It induced G 2 /M arrest that in U937 cells was associated with a marked decrease in the protein expressions of cyclin A, cyclin B, and cyclin-dependent kinase Cdk1. HEAMQ-induced apoptosis was accompanied with up-regulation of the protein expression of Bax and down-regulation of the protein expression of Bcl-2, Mcl-1, XIAP, and survivin, resulting in cytochrome c release and activation of caspases. Inhibitors of JNK (SP600125) and p38 MAPK (SB203580) suppressed HEAMQ-induced apoptosis and G 2 /M phase arrest, attenuated the activation of Bax, and blocked down-regulation of Bcl-2, XIAP and survivin in HEAMQ-treated U937 cells. In addition, combinations of HEAMQ with cisplatin and temozolomide resulted in synergistic inhibition of cell growth, producing long-term survivors of L1210 tumor-bearing mice. In conclusion, these results indicate that HEAMQ antineoplastic activity toward leukemia cells is associated with cell cycle arrest and apoptosis. The in vivo studies further confirmed the antitumor activity of HEAMQ and highlighted that this agent could be used to further increase therapeutic efficacies of traditional chemotherapeutic agents.
Cancer is a serious disease with a complex pathogenesis. A number of chemotherapeutic drugs have been developed to treat cancer. These drugs exert their antiproliferative and DNA damaging activities by disturbing the cell cycle progression and by induction of apoptosis [1] . Cell cycle progression is regulated by the coordinated action of cyclin-dependent protein kinases in association with specific regulatory cyclin proteins. Activation of the complex of Cdk1, Cdk2 with cyclin A and cyclin B is essential for transition of cells from G 2 to the M phase of the cell cycle [2] . Activation of caspases is regulated by various cellular proteins including members of the inhibitor of apoptosis (IAP) or Bcl-2 families [3, 4] . Previous studies have demonstrated that some Bcl-2 family members (Bax, Bcl-X L , Mcl-1, Bid and Bcl-2) that are located on the mitochondrial membrane can alter its permeability and trigger the activation of caspases leading to apoptosis [5] . The mitogen-activated protein kinase (MAPK) superfamily is important mediator of apoptosis induced by stress stimuli. JNK and p38 MAPK pathways are activated in response to chemicals and environmental stress, while the ERK cascade, activated by mitogenic stimuli, is critical for proliferation and survival [6, 7] . Recent evidence indicates that JNK signaling pathway affect the members of the Bcl-2 family. JNK can act as an activator in eliciting mitochondrial translocation of Bax [8] . Activation of p38 MAPK distorted mitochondrial function via an increase in the ratio of Bax and anti-apoptotic members leading to an increase in mitochondrial membrane permeability, the release of cytochrome c, and activation of caspases [9] .
Quinazolinone is a naturally occurring alkaloid found in a variety of bioactive natural products and possesses wide range of biological activities. Its derivatives have found attractive applications as pharmaceutics. They are used as antibacterial, antimalarial, antileishmanial, antituberculosis, antiinflammatory, antirheumatic, antiulcer, anticonvulsant or cardiac stimulant agents [10, 11] . It has been showed that they possess potent cytotoxic and antitumor activities by inhibiting of Pglycoprotein, topoisomerases I and II, PDGF receptor tyrosine kinase or PI3-kinase-related kinases (PIKKs). Some quinazolinones induce cell cycle arrest, generate reactive oxygen species, disrupt mitochondrial membrane potential, induce single-strand DNA breaks and activate caspases [10] [11] [12] [13] [14] .
In continuation to our effort on the design of potent anticancer agents, novel quinazolinone-based nonclassical antifolates were prepared and their antiproliferative potential was assessed [15] . In our pilot study, we found that many of these compounds exhibited potent cytotoxicity against leukemia cells. Among them, 2-[N-(2´-Hydroxyethyl)ami no]methyl-3H-quinazolin-4-one (HEAMQ) was found to be the most potent compound toward leukemia cells, with activity comparable to that of methotrexate, with IC 50 value in nM range [16] . Additionally, HEAMQ proved to be multitargeted agent active toward various cancer cell lines (e.g. HL-60, U937, L1210, A549, Capan-1, HCC1837).
In this study, we report that antineoplastic activity of HEAMQ toward U937 and L1210 leukemia cells is associated with G 2 /M cell cycle arrest, down-regulation of cyclin-dependent protein kinases, dysregulation of Bcl-2 family members and induction of apoptosis in leukemia cells. Importantly, we found that combinations of HEAMQ with traditional chemotherapeutic agents resulted in synergistic inhibition of leukemia cell growth in vitro and in vivo.
Materials and methods
Chemicals. 2-[N-(2´-Hydroxyethyl)amino]methyl-3H-quinazolin-4-one (HEAMQ) was prepared as described previously [15] . Chromatographically pure HEAMQ was dissolved in 100% DMSO. Final concentration of DMSO never exceeded 0.05% (v/v) in either control or treated cells. RPMI 1640 medium, fetal calf serum (FCS), phosphate buffer saline (PBS), L-glutamine, penicillin and streptomycin were obtained from Biocom (Slovakia). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), DMSO, ribonuclease A (RNAse), propidium iodide (PI), SB203580, SP600125, PD98059, cisplatin and temozolomide were purchased from Sigma-Aldrich (St Louis, MO, USA). Primary and HRP-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PVDF membrane was purchased from Bio-Rad Laboratories Ltd. (Bio-Rad, CA, USA), Pierce ® ECL Western Blotting Substrate was obtained from Thermo Fisher Scientific (Thermo Scientific, IL, USA) and Protease inhibitor cocktail tablets were purchased from Roche Applied Science (Roche Diagnostics GmbH, Vienna, Austria). The colorigenic synthetic peptide substrates, Ac-DEVD-pNA and Ac-LEHD-pNA were obtained from Calbiochem (La Jolla, CA, USA).
Cells. The human promonocytic U937 and murine L1210 lymphoblastic cell lines, obtained from the ATCC (Rockville, MD, USA), were cultured in RPMI 1640 medium supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), L-glutamine (292.3 μg/ml) and 10% heat-inactivated FCS in an atmosphere of 5% CO 2 in humidified air at 37°C.
Cell viability assay. Cell viability was assayed using a MTT assay [17] . Briefly, exponentially growing U937 or L1210 cells (1.5 x 10 5 cells/ml) were incubated in 96-well microtiter plates with medium containing 5, 25, 100 and 250 nM HEAMQ or combination of HEAMQ with 1 and 2 µM cisplatin or with 25 and 100 µM temozolomide in the final volume of 200 μl. After 6, 12, 18 and 24 h drug incubation at 37°C, 50 μl of MTT (1 mg/ml PBS) was added to each well followed by 4 h incubation at 37°C. Cells were centrifuged, supernatants were discarded and pellets were dissolved in 150 μl of DMSO. OD 540nm was determined by Microplate reader.
Analysis of drug combinations. The MTT data were analyzed using Calcusyn program to determine the IC 50 of each drug alone. The combination index (CI)-isobologram by Chou and Talalay [18] was used to analyze drug combinations. Variable ratios of drug concentrations were used and mutually exclusive equations were applied to determine the CIs. Each CI was calculated from the mean affected fraction at each drug ratio concentration (triplicate). CI > 1, CI = 1, and CI < 1 indicate antagonism, additive effect, or synergism, respectively.
Cell cycle measurement. U937 and L1210 cells treated with 25 and 70 nM HEAMQ for 12 and 24 h were harvested, washed in PBS, and exposed to 0.1% Triton X-100 in PBS supplemented with RNAse (50 μg/ml) for 25 min at 37°C. DNA was stained by PI (50 μg/ml) for 20 min at 4°C. Samples were analyzed by EPICS XL flow cytometry (Beckman Coulter Company, CI, USA), with the use of software provided by the manufacturer.
Detection of caspase-3 and caspase-9 activities. U937 and L1210 cell treated with 70 nM HEAMQ for 0 -24 h were collected, washed with PBS and resuspended in lysis buffer (50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 10 mM EGTA). Cell lysates were clarified by centrifugation (16.000 g, 10 min, 4°C). Cleared lysates containing 50 μg of proteins were incubated with 100 μM of enzyme-specific colorigenic substrates (Ac-DEVD-pNA for caspase-3, Ac-LEHD-pNA for caspase-9) at 37°C for 2 h. The activity of caspase-3 and caspase-9 was determined as the cleavage of the colorimetric substrate by measuring the OD 504nm .
Western blot analysis. U937 cells treated with 70 nM HEAMQ for 0 -24 h were collected, washed twice with PBS and lysed in lysis buffer (25 mM Tris-HCl (pH 7.2), 0.1% SDS, 0.1% Triton X-100, 150 mM NaCl, 1 mM EDTA, protease inhibitors) for 30 min at 4°C. Supernatants were cleared by centrifugation (16.000 g, 3 min, 4°C). Proteins (50 μg) were resolved on 10% SDS-PAGE gel and transferred to PVDF membrane. Membrane was blocked and proteins were detected using corresponding primary antibodies, followed by incubation with secondary antibodies. The signal was visualized using an ECL detection kit.
Cytochrome c assay.
Isolation of cytosolic and mitochondrial fractions was performed according to the Cytochrome c ELISA Kit protocol (MBL International Corporation). Briefly, about 5 x 10 6 U937 cells treated with 25 and 70 nM HEAMQ for 12 h were collected, washed with PBS and homogenized in a homogenizing buffer. Homogenates were centrifuged (10.000 g, 30 min, 4°C) and supernatants were collected and used as cytosolic fractions. Pellets were resuspended in ice cold buffer-2 and sonicated for three times (20 sec, 4°C). Homogenates were centrifuged (10.000 g, 15 min, 4°C) and supernatants were collected and used as mitochondria fractions. Cytosolic and mitochondrial fractions were assayed separately for cytochrome c using the Cytochrome c ELISA kit by measuring the OD 450nm .
MAPK inhibitor treatment. To investigate the effect of MAPK inhibitors on HEAMQ-induced cell cycle arrest and apoptosis, cells were preincubated for 2 h with 20 μM SP600125 (JNK inhibitor), 20 μM SB203580 (p38 inhibitor) or 20 μM PD98059 (ERK inhibitor) before the addition of 70 nM HEAMQ.
Animals. Inbred DBA/2J mice of both sexes (weighing 18 -22g) were obtained from the breeding facility of the Cancer Research Institute of SAS (Bratislava, Slovakia). The animals were reared under standard conditions. Food and water were provided ad libitum. All experiments were performed in full adherence with the European Community Guidelines principles for the care and use of laboratory animals.
In vivo experiment. L1210-leukemia bearing mice were used as antileukemic model of therapy [19] . The experimental animals were intraperitoneally implanted with L1210 leukemia cells (1 x 10 5 cells per mouse). The chemotherapy was started 1 day later as a single dose of 2.5 mg/kg of cisplatin, 15 mg/kg of temozolomide, 4 mg/kg of HEAMQ and combination of 2.5 mg/kg of cisplatin with 4 mg/kg of HEAMQ or 15 mg/kg of temozolomide and 4 mg/kg of HEAMQ. The drugs were administered intraperitoneally (0.5 ml per mouse). Animals were observed daily for the development of ascites and leukemia related death. Mean survival time (MST) and percentage of increase of life span (% ILS) were calculated and compared with MST of untreated control group.
Statistics. The data are expressed as the means ± SD of three independent experiments. The median and standard deviation were calculated using Excel software (Microsoft Office). The statistical significance of the results obtained was evaluated by a Student´s t-test, with probability values of P < 0.05 and P < 0.001 being considered as significant or highly significant, respectively.
Results
Effect of HEAMQ on cell viability. To check the effect of HEAMQ on cell growth, U937 and L1210 cells were treated with increasing concentrations of HEAMQ for 0 -24 h, and cell viability was assessed by MTT assay. As presented in Figure  1 , viability of U937 and L1210 cells decreased in a dose-and time-dependent manner with an IC 50 values of 68.5 nM for U937 and of 60.2 nM for L1210 cells at 24 h treatment.
Effect of HEAMQ on cell cycle. To investigate the mechanisms associated with HEAMQ-induced inhibition of cell proliferation, the effects of HEAMQ treatment on cell cycle profile of U937 and L1210 cells was examined. As presented in Table 1 , cells treated with HEAMQ were significantly accumulated in the G 2 /M phase of the cell cycle. 70 nM HEAMQ treatment for 24 h increased the percentage of cells in the G 2 /M phase from 17.9% to 57.8% for U937 and from 11.6% to 48.2% for L1210 cells, with a parallel reduction in the percentage of cells in G 0 /G 1 and S phases. These results suggested that HEAMQ inhibits cell proliferation through the G 2 /M phase arrest of the cell cycle.
Induction of apoptosis by HEAMQ. To determine whether HEAMQ induces cell death through apoptotic pathway, the . In addition, a marked increase in the activity of both caspase-9 and caspase-3 was detected in cells treated with 70 nM HEAMQ (Figure 2 ) in the fashion coinciding with sub-G 0 peaks (Table 1) . Taken together, we conclude that HEAMQ is a potent inducer of apoptosis of U937 and L1210 cells.
Effect of HEAMQ on the expression of cell cycle regulating proteins.
To evaluate the role of the cell cycle regulating 70 nM HEAMQ for 0 -24 h resulted in down-regulation of Bcl-2 and Mcl-1 expression, while Bax expression was notably up-regulated. Alternatively, the level of Bcl-X L and Bid proteins were unaltered. In addition to Bcl-2 family proteins, the IAP family proteins regulate apoptotic signaling cascade by blocking caspase activities [20] . The expression of two members of IAP family proteins, survivin and XIAP, were examined in HEAMQ-treated cells. As presented in Figure 4 , treatment of U937 cells with HEAMQ resulted in reducing protein expression of survivin and XIAP.
HEAMQ induces apoptosis by mitochondrial pathway. Mitochondria play a critical role in apoptosis by modulating Bcl-2 family members, such as Bcl-2, Mcl-1 and Bax, and releasing apoptogenic factors, such as cytochrome c [4] . As shown in Figure 4 , HEAMQ treatment elicited an increase in Bax expression and a decrease in Bcl-2 and Mcl-1 expression in U937 cells. Consistent with these results, increase in cytochrome c release into cytosol was noted after exposure of U937 cells to HEAMQ ( Figure 5 ). These results suggested that HEAMQ-induced apoptosis is mediated through a mitochondria-dependent pathway.
Effect of MAPK inhibitors on HEAMQ-induced G 2 /M phase arrest and apoptosis. To demonstrate that MAPK pathways are involved in mediating the HEAMQ-induced apoptosis and G 2 /M phase arrest, the effects of three highly specific MAPK inhibitors, namely SB203580 (p38 inhibitor), SP600125 (JNK inhibitor) and PD98059 (ERK inhibitor) on the cytotoxic effect of HEAMQ were evaluated. As shown in Table 2 , HEAMQ-induced apoptosis and cell cycle arrest were markedly attenuated by pretreatment of cells with SP600125 and SB203580. However, HEAMQ-induced apoptosis and G 2 / M phase arrest were not affected by ERK inhibitor (PD98059) pretreatment. These results revealed that HEAMQ-induced apoptosis and cell cycle arrest are related to JNK/p38 MAPK signaling pathway in U937 and L1210 cells. To further elucidate whether the pathways of JNK and p38 MAPK are involved in downstream molecular events of apoptosis, U937 cells were pretreated with SP600215 and SB203580 for 2 h, and then incubated with HEAMQ for another 24 h. As shown in Figure 6 , both inhibitors blocked HEAMQinduced up-regulation of Bax. Likewise, HEAMQ-induced down-regulation of Bcl-2, survivin and XIAP was markedly abrogated by SP600215 and SB203580. These biochemical changes reinforced the fact that HEAMQ-induced apoptosis is mediated through activation of JNK and p38 MAPK. Taken together, JNK and p38 MAPK activation plays a vital role in HEAMQ-induced apoptosis and G 2 /M cell cycle phase arrest in U937 cells.
Effect of HEAMQ on therapeutic efficacies of cisplatin and temozolomide.
To reveal full therapeutic potential of HEAMQ for combination chemotherapy, ability of HEAMQ to modulate therapeutic efficacies of cisplatin and temozolomide was tested. As presented in Table 3 , HEAMQ increased the efficacy of both chemotherapeutics. Drug combination studies by MTT test demonstrated that HEAMQ combined with cisplatin or temozolomide synergistically enhanced their antiproliferative activities (CI<1).
In vivo experiment. To check the therapeutic efficacy of HEAMQ under in vivo conditions, combination chemotherapy of HEAMQ with cisplatin or temozolomide was tested using L1210-leukemia bearing mice. As showed in Figure 7 and Table 4 , the synergistic action of HEAMQ was registered for its combination with cisplatin or temozolomide, respectively. This resulted in significant increase in life span for combinations of HEAMQ with cisplatin (85.7%) or HEAMQ with temozolomide (92.9%) compared to single treatment of L1210-leukemia bearing mice with cisplatin (29.8%), temozolomide (22.6%) or HEAMQ (33.3%).
Discussion
Successful treatment of leukemia cells with chemotherapeutic agents largely depends on their ability to induce cell cycle arrest and apoptosis. Therefore, novel inducers of apoptosis provide a new therapeutic approach for antineoplastic treatment. Several Cdks regulate the cell cycle progression in mammalian cells [2] . Among the Cdks that regulate cell cycle progression, Cdk1 and Cdk2 kinases are activated in association with cyclins A and B during the G 2 /M phase transition. In this study, we showed that novel quinazolinone-based nonclassical antifolate, HEAMQ, abrogates progression of cells in G 2 /M phase (Table 1 ) through decreasing expression of Cdk1, cyclin A and cyclin B (Figure 3 ). These data suggest that cell cycle arrest induced by HEAMQ is mediated by limiting the supply of Cdk1, cyclin A and cyclin B, which are essential executors in regulating transition into mitosis. Thus, it is plausible that alterations in cell cycle associated proteins lead to block at G 2 /M phase in HEAMQ-treated leukemia cells.
Apoptosis is tightly regulated process under control of several signaling pathways, such as caspase and mitochondrial pathways [3] [4] [5] 9, 20] . In our study, HEAMQ treatment caused activation of caspase-9 and caspase-3 in a time-dependent manner (Figure 2) , that was consistent with accumulation of cells in the sub-G 0 phase (Table 1) . Moreover, a timedependent increase in cytosolic cytochrome c was detected in HEAMQ-treated cells ( Figure 5 ). Bcl-2 family proteins, including the anti-apoptotic Bcl-2, Bcl-X L and Mcl-1, and the pro-apoptotic Bad, Bid and Bax proteins have been reported to regulate cytochrome c release from mitochondria [4, 5] . It has been reported that proto-oncogene Bcl-2, which encodes an inner mitochondrial protein, is antagonizing apoptosis and its decreased expression or changes in post-transcriptional regulation might contribute to the drug-mediated lethality [5, 21] . On the contrary, overexpression of Bax accelerates apoptosis induced by different stress stimuli in many cell lines [22, 23] . Consistent with these observations, down-regulation of Bcl-2 and Mcl-1, increase in expression of Bax, and release of cytochrome c were noted with HEAMQ-treated leukemia cells (Figure 4 and Figure 5 ). IAPs have been reported to inhibit apoptosis via their function in inhibition of caspase-3 and caspase-7 activation. IAPs are also able to abrogate cytochrome c-induced activation of caspase-9 [3, 5] . Our data 25 MST -mean survival time, ILS -increase of life span, *P < 0.05, **P < 0.001.
reveal that the protein expression of XIAP and survivin was decreased by HEAMQ treatment (Figure 4 ). Taken together, our results clearly demonstrated that dysregulation of Bcl-2 family members by HEAMQ treatment led to mitochondrialdependent apoptotic death of U937 cells.
Recent evidence indicates that the MAPK family proteins are important mediators of apoptosis induced by stress stimuli [6, 7] . JNK signaling pathway has been reported to affect the members of the Bcl-2 family by eliciting mitochondrial translocation of Bax [8] . Importantly, p38 MAPK regulates the ratio of Bax and anti-apoptotic members, whose dysregulation is leading to an increase in mitochondrial membrane permeability, the release of cytochrome c, and activation of caspases [9] . In the present study, HEAMQ-induced Bcl-2, XIAP and survivin down-regulation and Bax up-regulation were abolished by pretreatment with JNK-specific inhibitor SP600125 and p38 kinase-specific inhibitor SB203580 ( Figure 6 ). These data suggest that JNK and p38 MAPK pathways are involved in HEAMQ-induced apoptosis in leukemia cells.
Since many chemotherapeutic drugs used for treatment of tumors could enhance or diminish action of other active agents and in vivo effectiveness of combination treatment is extremely important for development of new chemotherapy agents [24, 25] , combination chemotherapy of HEAMQ with cisplatin and temozolomide under in vitro and in vivo conditions was tested. Results of MTT study showed that HEAMQ significantly enhanced therapeutic efficacy when used in combination with cisplatin or temozolomide (Table  3 ). This effect probably involves activation of apoptosis by HEAMQ through alteration of anti-apoptotic and pro-apoptotic proteins making thus leukemia cells more sensitive to chemotherapeutic drugs. Although the exact mechanism of synergy of cisplatin and HEAMQ is not fully understood, there is accumulating evidence of a key role for p38 MAPK pathway activation in the cellular response to cisplatin. Additionally, it has been postulated that prolonged activation of JNK pathway is sensitizing cells to cisplatin [26] . As HEAMQ-induced apoptosis features are blocked by pretreatment of cells with JNK and p38 inhibitors ( Figure 6 and Table 2 ), it is plausible that activating JNK and p38 MAPK pathway by HEAMQ increases sensitivity of cells to cisplatin. Interestingly, combination of HEAMQ with cisplatin or temozolomide in vivo followed synergistic action detected in vitro, and increased life span of L1210-leukemia bearing mice was observed when combinations of HEAMQ with cisplatin or temozolomide were applied, compared to single treatment regiment ( Figure 7 and Table 4 ).
Taken together, our results clearly demonstrated that novel quinazolinone-based nonclassical antifolate, HEAMQ, possesses strong antineoplastic activity associated with G 2 /M cell cycle arrest, down-regulation of cyclin-dependent protein kinases, dysregulation of Bcl-2 family members and induction of apoptosis, and highlighted that this agent could be used to further increase therapeutic efficacies of traditional chemotherapeutic agents.
